Trial Profile
A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Jun 2022
Price :
$35
*
At a glance
- Drugs Budigalimab (Primary) ; Revdofilimab (Primary)
- Indications Advanced breast cancer; Bladder cancer; Carcinoma; Cholangiocarcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Malignant melanoma; Mesothelioma; Mouth neoplasm; Non-small cell lung cancer; Oropharyngeal cancer; Ovarian cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors AbbVie
- 21 Apr 2022 Status changed from active, no longer recruiting to completed.
- 24 Jan 2022 Planned End Date changed from 30 Sep 2021 to 25 Feb 2022.
- 24 Jan 2022 Planned primary completion date changed from 29 Sep 2021 to 25 Feb 2022.